Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5495068 | 1.00 | CA1 (0.33) | CA1CA2CA9GRIN2DGRIN3B | |
| SCHEMBL27494904 | 0.84 | MAPT (0.40) | CA1CA2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL27494903 | 0.84 | MAPT (0.40) | CA1CA2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL5493590 | 0.83 | SLC7A5 (0.39) | CA1CA2CA9 | |
| SCHEMBL5493588 | 0.83 | SLC7A5 (0.39) | CA1CA2CA9 | |
| SCHEMBL19105215 | 0.81 | PKM (0.32) | CA1CA2CA9PKMSMN1; SMN2 | |
| SCHEMBL11915792 | 0.81 | ELANE (0.42) | CA1CA2CA9PKMSMN1; SMN2 | |
| SCHEMBL935390 | 0.78 | KMT2A (0.43) | — | |
| SCHEMBL17278283 | 0.78 | SLC7A5 (0.45) | MTORRAB9A | |
| SCHEMBL12831909 | 0.77 | PKM (0.31) | PKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0961779-A1 | SUBSTITUTED AMINO BICYCLIC-$g(b)-LACTAM PENAM AND CEPHAM DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | SYNPHAR LABORATORIES INC. (CA) | 1999-12-08 | — | — | EP | claimed |
| WO-1998032766-A1 | SUBSTITUTED AMINO BICYCLIC-β-LACTAM PENAM AND CEPHAM DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | SYNPHAR LABORATORIES INC. (US) | 1998-07-30 | — | — | WO | claimed |
| CN-116785269-A | Homotaurine derivatives and uses thereof | 润佳（苏州）医药科技有限公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-110709523-B | Sequencing reaction method using tagged nucleosides obtained via PICTET SPENGLER reaction | 豪夫迈·罗氏有限公司 | 2023-07-11 | — | — | CN | disclosed |
| US-11293060-B2 | Method for labeling of aldehyde containing target molecules | Roche Sequencing Solutions, Inc. (US) | 2022-04-05 | — | — | US | disclosed |
| EP-3609897-A1 | A METHOD FOR LABELING OF ALDEHYDE CONTAINING TARGET MOLECULES | H. Hoffnabb-La Roche Ag (CH) | 2020-02-19 | — | — | EP | disclosed |
| EP-3610040-A1 | A METHOD FOR SEQUENCING REACTION WITH TAGGED NUCLEOSIDE OBTAINED VIA PICTET SPENGLER REACTION | H. Hoffnabb-La Roche Ag (CH) | 2020-02-19 | — | — | EP | disclosed |
| WO-2018191389-A1 | A METHOD FOR SEQUENCING REACTION WITH TAGGED NUCLEOSIDE OBTAINED VIA PICTET SPENGLER REACTION | Roche Sequencing Solutions, Inc. (US) | 2018-10-18 | — | — | WO | disclosed |
| WO-2018189214-A1 | A METHOD FOR LABELING OF ALDEHYDE CONTAINING TARGET MOLECULES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-10-18 | — | — | WO | disclosed |
| WO-2017075535-A1 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| EP-2882459-A1 | DRUG DELIVERY VEHICLE COMPRISING CONJUGATES BETWEEN TARGETING POLYAMINO ACIDS AND FATTY ACIDS | University of North Texas Health Science Center (US) | 2015-06-17 | — | — | EP | disclosed |
| WO-2006078899-A2 | MUCIN HYPERSECRETION INHIBITORS BASED ON THE STRUCTURE OF MANS AND METHODS OF USE | BIOMARCK PHARMACEUTICALS, LTD. (US) | 2006-07-27 | — | — | WO | disclosed |
| US-6590061-B1 | Synthetic polypeptide or peptides having narrow molecular weight distribution used as telechelic polymers for synthesis of block or graft copolymers | INSTITUTE OF MACROMOLECULAR CHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2003-07-08 | — | — | US | disclosed |
| WO-2002100885-A2 | A PENTA- OR TETRAPEPTIDE BINDING TO SOMATOSTATIN RECEPTORS AND THE USE OF THE SAME | NOVASPIN BIOTECH GMBH (DE) | 2002-12-19 | — | — | WO | disclosed |
| EP-1088020-B1 | FUNCTIONALISED POLYMERS OF ALPHA-AMINO ACIDS AND THE METHOD OF PREPARATION THEREOF | USTAV MAKROMOLEKULARNI CHEMIE (CZ) | 2002-12-18 | — | — | EP | disclosed |
| US-6232305-B1 | ANTICANCER AGENTS; BONE DISORDERS; ANTIARTHRITIC AGENTS; RESPIRATORY SYSTEM DISORDERS | NAEJA PHARMACEUTICAL INC. (CA) | 2001-05-15 | — | — | US | disclosed |
| EP-1088020-A1 | FUNCTIONALISED POLYMERS OF ALPHA-AMINO ACIDS AND THE METHOD OF PREPARATION THEREOF | USTAV MAKROMOLEKULARNI CHEMIE AKADEMIE VED CESKE REPUBLIKY (CZ) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999064495-A1 | FUNCTIONALISED POLYMERS OF α-AMINO ACIDS AND THE METHOD OF PREPARATION THEREOF | ÚSTAV MAKROMOLEKULÁRNÍ CHEMIE AKADEMIE VĚD ČESKÉ REPUBLIKY (CZ) | 1999-12-16 | — | — | WO | disclosed |
| EP-0961779-A1 | SUBSTITUTED AMINO BICYCLIC-$g(b)-LACTAM PENAM AND CEPHAM DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | SYNPHAR LABORATORIES INC. (CA) | 1999-12-08 | — | — | EP | disclosed |
| WO-1998032766-A1 | SUBSTITUTED AMINO BICYCLIC-β-LACTAM PENAM AND CEPHAM DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | SYNPHAR LABORATORIES INC. (US) | 1998-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11293060-B2 | Method for labeling of aldehyde containing target molecules | NUDT1, RNGTT, DERA | CA1 2925/4885CA2 2590/4885CA9 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.